Breast Cancer
Latest News
Advertisement
Latest Videos
Podcasts
Advertisement
More News
112 First-Line (1L) Datopotamab Deruxtecan (Dato-DXd) vs Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer (mTNBC) for Whom Immunotherapy Was Not an Option: Primary Results From the Randomized, Phase 3 TROPION-Breast02 Trial
ByRebecca Dent, MD,Zhimin Shao,Peter Schmid, MD,Javier Cortés, MD,David W. Cescon,Shighira Saji,Kyung Hae Jung,Thomas Bachelot,Shouman Wang,Gul Basaran,Yee Soo Chae,Rofhiwa Mathiba,Shin-Cheh Chen,Agostina Stradella,Nicola Battelli,Naoki Niikura,Kechen Zhao,Petra Vukovic,Michah Maxwell,Tiffany Traina, MD, FASCO
TIP113 HERTHENA-PanTumor01 (NCT06172478): Expansion of a Global Phase 2 Trial of HER3-DXd in Patients With Advanced/Metastatic HR+/HER2− Breast Cancer
ByFunda Meric-Bernstam, MD,Christos Fountzilas,Izuma Nakayama,Takahiro Kogawa,Tomohiro Nishina,Thomas Powles, MBBS, MCRP, MD,Jin Won Kim,Yen-Yang Chen,Francois Ghiringhelli,Valentina Gambardella,James W. Smithy,Jérome Fayette,Fan Jin,Y.K. Chang,Kendall Sullivan,Sue Yueh,Ajlan Atasoy,Andrea Sporchia,Ragini Kudchadkar, MD,Hidetoshi Hayashi
117 Risk of Recurrence (ROR) Among Patients With HR+/HER2− Early Breast Cancer (EBC) Involving 1-3 Axillary Lymph Nodes (N1): A Real-World Evaluation
ByPedram Razavi,Joyce O’Shaughnessy, MD,Lasika Seneviratne, MD,Mehnaj Ahmed,Ashley Roush,Siddhi Korgaonkar,Abigail Hitchens,Keith L. Davis,Anton Safonov,Mark Robson, MD,Yanjun Ma,Brittni Smith,Lorraine Brisbin,Siraje Mahmud,Laura Ensley,Robert Milford,Elan Ingram,Vaidyanathan Ganapathy,Corinth Auld,Mumbi E. Kimani,Liz Santarsiero,L. Johnetta Blakely, MD
122 Adjuvant Ribociclib (RIB) Plus Nonsteroidal Aromatase Inhibitor (NSAI) in Patients With HR+/HER2− Early Breast Cancer (EBC): NATALEE 5-Year Outcomes
ByJohn Crown,Daniil Stroyakovskii,Denise A. Yardley, MD,Chiun-Sheng Huang,Peter A. Fasching,Aditya Bardia, MD, MPH, FASCO,Stephen Chia,Seock-Ah Im,Miguel Martin, MD, PhD,Binghe Xu,Carlos H Barrios,Michael Untch, MD, PhD,Rebecca Moroose,Sara A. Hurvitz, MD,Gabriel N. Hortobagyi, MD, FACP,Dennis J. Slamon, MD, PhD,Frances Visco,Gonzalo Spera,Zheng Li,Sherene Loi, MD, PhD
There are reimbursement and infrastructure challenges in oncology care, with the need for systemic changes to provide patients with lifesaving behavioral interventions.
130 Sacituzumab Govitecan (SG) + Pembrolizumab (Pembro) Vs Chemotherapy (Chemo) + Pembro in Previously Untreated PD-L1–Positive Advanced Triple-Negative Breast Cancer (TNBC): Primary Results From the Randomized Phase 3 ASCENT-04/KEYNOTE-D19 Study
BySara M. Tolaney, MD, MPH,Evandro de Azambuja,Kevin Kalinsky, MD, MS,Sherene Loi, MD, PhD,Sung-Bae Kim,Clinton Yam,Bernardo Rapoport, MD,Seock-Ah Im,Barbara Pistilli,Wassim McHayleh,David W. Cescon,Junichiro Watanabe,Manuel Alejandro Lara Banuelas,Ruffo Freitas-Junior,Javier Salvador Bofill,Maryam Afshari,Dianna Gary,Lu Wang,Catherine Lai, MD, MPH,Peter Schmid, MD
Clearance of a novel AI platform may represent an important advance in personalizing treatments for patients with early-stage breast cancer.
Results from the CHALLENGE trial showed that activity can reduce cancer recurrence for patients with colorectal, breast, and prostate cancers.
131 Primary Results From ASCENT-03: A Randomized Phase 3 Study of Sacituzumab Govitecan (SG) vs Chemotherapy (Chemo) in Patients (pts) With Previously Untreated Advanced Triple-Negative Breast Cancer (TNBC) Who Are Unable to Receive PD-(L)1 Inhibitors (PD-[L]1i)
ByJavier Cortés, MD,Aditya Bardia, MD, MPH, FASCO,Kevin Punie,Carlos Barrios,Sara A. Hurvitz, MD,Andreas Schneeweiss, MD,Joohyuk Sohn,Eriko Tokunaga,Adam M. Brufsky, MD, PhD,Yeon Hee Park,Binghe Xu,Roberto Hegg,Mafalda Oliveira,Alessandra Fabi,Natalya Vaksman,Theresa Valdez,Xinrui Zhang,Catherine Lai, MD, MPH,Sara M. Tolaney, MD, MPH
Jennifer A. Ligibel, MD, discussed the complex link between weight loss and cancer risk, exploring data from bariatric surgery and the emerging role of GLP-1s.
Advertisement
Advertisement
Trending on CancerNetwork
1
Current Treatment Landscape of HER2-Positive Metastatic Breast Cancer and Phase 3 Trial Overview
2
The Moonlight Shift: Dr Joshua Richter on Myeloma, Myths, and the C-Word
3
FDA Approves Afami-cel in Metastatic Synovial Sarcoma
4
Zanzalintinib/Atezolizumab Misses Survival End Point in Non-MSI-H mCRC Subgroup
5